🇺🇸 FDA

Intelligence · Clinical Pipeline

GSK Glaxo Smith Pipeline

All ClinicalTrials.gov programs at GSK Glaxo Smith — phase, modality, and trial IDs.

Programs
70

Quick answer

GSK Glaxo Smith has 70 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. 0.9% Sodium Chloride Injection

    GlaxoSmithKline

    Non-alcoholic Fatty Liver Disease

    phase 2 small molecule active

    1 trial

  2. A Dose-Finding, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of GSK4532990 for Steatohepatitis in Adults with Alcohol-related Liver Disease (ALD)

    GlaxoSmithKline

    Liver Diseases, Alcoholic

    phase 2 other active

    1 trial

  3. A Multi-Center, Single Arm, Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of GSK4527226 [AL101] in Participants with Early Alzheimer’s Disease.

    GlaxoSmithKline

    Alzheimer's Disease

    phase 2 other active

    1 trial

  4. A Phase 1/2 First-Time-in-Human, open-label, multicenter, dose escalation and expansion study of GSK5458514 PSMA targeting T cell engager alone or in combination with other anti-cancer agents in adult participants with metastatic castration-resistant prostate cancer (mCRPC)

    GlaxoSmithKline

    Neoplasms, Prostate

    phase 2 other active

    1 trial

  5. A Phase 1/2 open-label, multicenter study of oral GSK5460025 alone or in combination with other anti-cancer agents in adult participants with Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) solid tumors.

    GlaxoSmithKline

    Neoplasms, Colorectal

    phase 2 other active

    1 trial

  6. A Phase 1b/2, multicenter, open-label study to evaluate the efficacy and safety of GSK5764227 alone and in combination in participants with previously treated advanced unresectable or metastatic gastrointestinal solid tumors

    GlaxoSmithKline

    Gastrointestinal Neoplasms

    phase 2 other active

    1 trial

  7. A Phase 2, Randomized, Open-label, Study of Momelotinib in Participants with Anemia due to Low-risk Myelodysplastic Syndrome.

    GlaxoSmithKline

    Myelodysplastic Syndrome

    phase 2 other active

    1 trial

  8. A Phase 2, Randomized, Parallel, Open-Label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Various Dosing Regimens of Single-Agent Belantamab Mafodotin (GSK2857916) in Participants with Relapsed or Refractory Multiple Myeloma (DREAMM-14)

    GlaxoSmithKline

    Multiple Myeloma

    phase 2 other active

    1 trial

  9. A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Subjects with Advanced Solid Tumors

    GlaxoSmithKline

    Ovarian Neoplasms

    phase 2 other active

    1 trial

  10. A prospective, multi-centre study (B-Sure) to evaluate long-term durability of treatment response in chronic hepatitis B participants with and without nucleos(t)ide therapy who have participated in a previous bepirovirsen treatment study.

    GlaxoSmithKline

    Chronic Hepatitis B

    phase 2 other active

    1 trial

  11. Alpharix suspensie voor injectie in een voorgevulde spuit Trivalent griepvaccin (gefragmenteerd virion, geïnactiveerd)

    GlaxoSmithKline

    Influenza, Human

    phase 2 small molecule active

    1 trial

  12. Alpharix suspensie voor injectie in een voorgevulde spuit Trivalent griepvaccin (gefragmenteerd virion, geïnactiveerd)

    GlaxoSmithKline

    Influenza, Human

    phase 2 small molecule active

    1 trial

  13. Amyvid 1900 MBq/mL solution for injection, Neuraceq 300 MBq/mL solution for injection, 0.9% (w/v) sodium chloride (Normal Saline), VIZAMYL 400 MBq/mL solution for injection, Amyvid 800 MBq/mL solution for injection

    GlaxoSmithKline

    Alzheimer's Disease

    phase 2 small molecule active

    1 trial

  14. Aprepitant

    GlaxoSmithKline

    Nausea and Vomiting

    phase 2 small molecule completed

    1 trial

  15. Arexvy powder and suspension for suspension for injection Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted)

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    phase 2 small molecule active

    1 trial

  16. Bendafolin 10 mg/ml Injektionslösung, Benda-5 FU 50 mg/ml Injektionslösung, Xtandi - 40 mg film-coated tablets, Zirabev 25 mg/ml concentrate for solution for infusion, BENDAFOLIN 10 mg/ml Injektionslösung, 5-FLUOROURACIL–EBEWE, 50 MG/ML, ROZTWÓR DO WSTRZYKIWAN I INFUZJI, 5-Флуороурацил Ебеве 50 mg/ml концентрат за инжекционен и инфузионен разтвор., Calciumfolinat Kabi 10 mg/ml Injektions-/Infusionslösung, 5-FU medac 50 mg/ml, Injektionslösung, Zirabev 25 mg/ml concentrate for solution for infusion

    GlaxoSmithKline

    Neoplasms

    phase 2 small molecule active

    1 trial

  17. Benlysta 200 mg solution for injection in pre-filled pen., Benlysta 200 mg solution for injection in pre-filled pen., Benlysta 200 mg solution for injection in pre-filled pen.

    GlaxoSmithKline

    Systemic Lupus Erythematosus

    phase 2 small molecule active

    1 trial

  18. Buffer S9b Solution for suspension for injection

    GlaxoSmithKline

    Hepatitis B, Chronic

    phase 2 small molecule active

    1 trial

  19. Buffer S9b Solution for suspension for injection

    GlaxoSmithKline

    Hepatitis B, Chronic

    phase 2 small molecule active

    1 trial

  20. CAPECITABINE ZENTIVA 150 mg, comprimé pelliculé, Capecitabine Accord 150 mg film-coated tablets, Oxaliplatin Bendalis 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Oxaliplatin AqVida 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Capecitabin "Zentiva", filmovertrukne tabletter, Capecitabina Zentiva 500 mg compresse rivestite con film., Capecitabine Zentiva 150 mg filmdragerade tabletter, Capecitabin "Zentiva", filmovertrukne tabletter, CAPECITABINE ZENTIVA 150 mg, comprimé pelliculé,

    GlaxoSmithKline

    MMRp/ MSS colon cancer

    phase 2 small molecule active

    1 trial

  21. Carboplatino Hikma 10 mg/ml soluzione per infusione, Avastin 25 mg/ml concentrate for solution for infusion., Cisplatino Accord Healthcare Italia 1 mg/ml concentrato per soluzione per infusione, JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Tumours, Gynecological

    phase 2 small molecule active

    1 trial

  22. DTPw-HBV/Hib-MenAC conjugate vaccine

    GlaxoSmithKline

    Diphtheria

    phase 2 mab completed

    1 trial

  23. Dectova 10 mg/mL solution for infusion

    GlaxoSmithKline

    Influenza, Human

    phase 2 small molecule active

    1 trial

  24. Extended Access of Momelotinib for Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ETMF)

    GlaxoSmithKline

    Primary Myelofibrosis (PMF), Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

    phase 2 other active

    1 trial

  25. FF/GSK573719

    GlaxoSmithKline

    Asthma

    phase 2 small molecule completed

    1 trial

  26. FF/GW642444M

    GlaxoSmithKline

    Asthma

    phase 2 small molecule completed

    1 trial

  27. Fluticasone Furoate

    GlaxoSmithKline

    Asthma

    phase 2 small molecule completed

    1 trial

  28. Fluticasone furoate (FF) (100 mcg)

    GlaxoSmithKline

    Asthma

    phase 2 small molecule completed

    1 trial

  29. Fluticasone propionate

    GlaxoSmithKline

    Asthma

    phase 2 small molecule completed

    1 trial

  30. GSK Biologicals' GSK2340274A (two different formulations)

    GlaxoSmithKline

    Influenza

    phase 2 mab completed

    1 trial

  31. GSK1070806

    GlaxoSmithKline

    Dermatitis, Atopic

    phase 2 small molecule terminated

    1 trial

  32. GSK221149A

    GlaxoSmithKline

    Obstetric Labour, Premature

    phase 2 small molecule completed

    1 trial

  33. GSK233705 12.5mcg

    GlaxoSmithKline

    Pulmonary Disease, Chronic Obstructive

    phase 2 small molecule completed

    1 trial

  34. GSK256066

    GlaxoSmithKline

    Asthma

    phase 2 small molecule completed

    1 trial

  35. GSK3196165 Dose 1

    GlaxoSmithKline

    Arthritis, Rheumatoid

    phase 2 small molecule completed

    1 trial

  36. GSK4527226

    GlaxoSmithKline

    Alzheimer's Disease

    phase 2 small molecule active

    1 trial

  37. GSK962040 50 mg

    GlaxoSmithKline

    Gastroparesis

    phase 2 small molecule terminated

    2 trials

  38. GW679769

    GlaxoSmithKline

    Postoperative Nausea and Vomiting

    phase 2 small molecule completed

    1 trial

  39. Isatuximab, Dexa-ratiopharm® 8 mg Injektionslösung, Fortecortin® 2 mg Tabletten, Revlimid 15 mg hard capsules, Zelvina 2.5 mg hard capsules, Revlimid 10 mg hard capsules, Revlimid 2.5 mg hard capsules, Zelvina 5 mg hard capsules, Zelvina 25 mg hard capsules, Imnovid 2 mg hard capsules, Imnovid 3 mg hard capsules, Zelvina 10 mg hard capsules, Revlimid 25 mg hard capsules, Imnovid 1 mg hard capsules, Dexamethason 8 mg GALEN® Tabletten, Nirogacestat, Isatuximab, Nirogacestat, Dexa 8 mg inject JENAPHARM Injekti

    GlaxoSmithKline

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  40. JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Relapsed/Refractory Tumors

    phase 2 small molecule active

    1 trial

  41. JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Neoplasms, Rectal

    phase 2 small molecule active

    1 trial

  42. JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Neoplasms, Head and Neck

    phase 2 small molecule active

    1 trial

  43. JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Neoplasms, Colorectal

    phase 2 small molecule active

    1 trial

  44. JEMPERLI 500 mg concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    GlaxoSmithKline

    Lung Cancer, Non-Small Cell

    phase 2 small molecule active

    1 trial

  45. Locally Sourced 0.9% Sodium Chloride

    GlaxoSmithKline

    Dermatitis, Atopic

    phase 2 small molecule active

    1 trial

  46. Locally Sourced 0.9% Sodium Chloride

    GlaxoSmithKline

    Dermatitis, Atopic

    phase 2 small molecule active

    1 trial

  47. NaCl 0.9% solution

    GlaxoSmithKline

    Meningitis, Meningococcal

    phase 2 small molecule active

    1 trial

  48. NaCl solution

    GlaxoSmithKline

    Herpes Simplex

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does GSK Glaxo Smith have?

70 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.